デフォルト表紙
市場調査レポート
商品コード
1410820

BCR-ABL検査市場:セグメント別規模、シェア、法規制、償還、2033年までの予測

BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
BCR-ABL検査市場:セグメント別規模、シェア、法規制、償還、2033年までの予測
出版日: 2023年12月14日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

白血病は、血液と骨髄に影響を及ぼす異種のがん群です。2つの一般的な亜型はリンパ性白血病と骨髄性白血病で、それぞれリンパ球と骨髄球に由来します。白血病は急速に進行するもの(急性)と緩徐に進行するもの(慢性)があり、20歳未満の小児および若年成人のがんによる死亡の主な原因となっています。白血病には標準的な病期分類はなく、未治療、寛解期、再発のいずれかに分類されます。

BCR-ABLはフィラデルフィア(Ph)染色体としても知られる突然変異であり、22番染色体上のBCR遺伝子と9番染色体上のABL1遺伝子の染色体相互転座によって形成されます。この転座の結果、BCR-ABL融合遺伝子が生じ、チロシンキナーゼシグナル伝達タンパク質である融合タンパク質が産生され、このタンパク質は構成的に活性化されるため、細胞分裂が制御不能になります。

BCR-ABL検査には、BCR-ABLin situ ハイブリダイゼーション(ISH)、BCR-ABL核酸増幅(NAATs)、BCR-ABL次世代シーケンシング(NGS)、BCR-ABLサンガーシーケンシング、BCR-ABLパイロシーケンシングおよび細胞遺伝学検査が含まれます。

当レポートは、世界のBCR-ABL検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されているBCR-ABL検査と競合情勢

  • 主要な業界動向の洞察
  • BCR-ABL検査のセグメント別総市場収益と2015年~2033年の市場展望
  • 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

  • BCR-ABL検査市場のSWOT分析
  • BCR-ABL検査市場に関する競合力学の洞察と動向
  • 国別の医療制度の概要
  • 国別の償還政策
  • 国別の医療技術に関する規制の状況
図表

List of Tables

Not Applicable

List of Figures

Not Applicable

目次

Abstract

BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BCR-ABL Tests market for the year 2020 and beyond. Leukemia is a heterogeneous group of cancers that affects the blood and bone marrow. Two common subtypes are lymphocytic leukemia's and myeloid leukemia's, which derive from lymphoid cells and myeloid cells, respectively. Leukemia can progress rapidly (acute), or slowly (chronic), and is the primary cause of deaths from cancer in children and young adults under the age of 20 years. There is no standard staging system for leukemia; the disease as described as untreated, in remission, or recurrent.

BCR-ABL is a mutation, also known as the Philadelphia (Ph) chromosome, which is formed by a reciprocal chromosomal translocation of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. This translocation results in a BCR-ABL fusion gene and production of a fusion protein - a tyrosine kinase signaling protein this is constitutively active, causing cells to divide uncontrollably.

The BCR-ABL tests include BCR-ABL In Situ Hybridization (ISH), BCR-ABL Nucleic Acid Amplification (NAATs), BCR-ABL Next Generation Sequencing (NGS), BCR-ABL Sanger Sequencing, BCR-ABL Pyrosequencing and Cytogenetics tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed BCR-ABL tests and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total BCR-ABL tests market revenue by segment and market outlooks from 2015-2033.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for BCR-ABL Tests market.
  • Competitive dynamics insights and trends provided for BCR-ABL Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Sysmex Corp, Bio-Techne Corp, Danaher Corp, Bio-Rad Laboratories Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Takara Bio Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the BCR-ABL Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to-

  • Understand the impact of COVID-19 on BCR-ABL Tests market.
  • Develop and design you're in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving BCR-ABL Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BCR-ABL Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific BCR-ABL Tests market from 2015-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable